[go: up one dir, main page]

WO2025010229A3 - T-cell receptors targeting foxm1 and methods of use thereof - Google Patents

T-cell receptors targeting foxm1 and methods of use thereof Download PDF

Info

Publication number
WO2025010229A3
WO2025010229A3 PCT/US2024/036413 US2024036413W WO2025010229A3 WO 2025010229 A3 WO2025010229 A3 WO 2025010229A3 US 2024036413 W US2024036413 W US 2024036413W WO 2025010229 A3 WO2025010229 A3 WO 2025010229A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell receptors
methods
foxm1
disclosure
receptors targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/036413
Other languages
French (fr)
Other versions
WO2025010229A2 (en
Inventor
Alexandre REUBEN
Minying ZHANG
John Victor HEYMACH
Gregory A. LIZEE
Peixin JIANG
Patrick Hwu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2025010229A2 publication Critical patent/WO2025010229A2/en
Publication of WO2025010229A3 publication Critical patent/WO2025010229A3/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides T-cell receptors comprising an antigen binding variable region that specifically binds an antigenic peptide derived from FOXM1. The present disclosure further provides activated or engineered T-cells comprising the T-cell receptors of the disclosure, and methods of making and using these T-cell receptors. Aspects of the disclosure further relate to a polypeptide comprising an antigen binding variable region comprising a CDR3 region of the disclosure.
PCT/US2024/036413 2023-07-06 2024-07-01 T-cell receptors targeting foxm1 and methods of use thereof Pending WO2025010229A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363512267P 2023-07-06 2023-07-06
US63/512,267 2023-07-06

Publications (2)

Publication Number Publication Date
WO2025010229A2 WO2025010229A2 (en) 2025-01-09
WO2025010229A3 true WO2025010229A3 (en) 2025-05-15

Family

ID=94172174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/036413 Pending WO2025010229A2 (en) 2023-07-06 2024-07-01 T-cell receptors targeting foxm1 and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2025010229A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273647A1 (en) * 2010-09-20 2013-10-17 Biontech Ag Antigen-Specific T Cell Receptors and T Cell Epitopes
US20170088895A1 (en) * 2015-09-29 2017-03-30 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2024123975A2 (en) * 2022-12-07 2024-06-13 Board Of Regents, The University Of Texas System A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130273647A1 (en) * 2010-09-20 2013-10-17 Biontech Ag Antigen-Specific T Cell Receptors and T Cell Epitopes
US20170088895A1 (en) * 2015-09-29 2017-03-30 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2024123975A2 (en) * 2022-12-07 2024-06-13 Board Of Regents, The University Of Texas System A t cell receptor recognizing an unmutated foxm1 epitope presented on hla-a*02:01

Also Published As

Publication number Publication date
WO2025010229A2 (en) 2025-01-09

Similar Documents

Publication Publication Date Title
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
HK1257518A1 (en) Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
IL277242B2 (en) Antibodies that bind cd39 and uses thereof
PH12019501464A1 (en) Novel anti-human transferrin receptor antibody capable of penetrating blood-brain barrier
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2020172528A8 (en) Albumin binding antibodies and use thereof
WO2005063816A3 (en) Monovalent antibody fragments useful as therapeutics
PT2173381E (en) Fc receptor-binding polypeptides with modified effector functions
WO2016207304A8 (en) Monoclonal anti-il-1racp antibodies
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
WO2005000086A3 (en) FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
MX2021012365A (en) Bispecific antibodies.
AU2002354806A1 (en) Parathyroid hormone antibodies and related methods
WO2022164886A3 (en) Chimeric antigen receptors targeting cd20
WO2021163562A3 (en) Compositions and methods comprising splicing-derived antigens for treating cancer
MX2022000081A (en) NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA ANTIGEN BINDING PROTEINS 1 (NY-ESO-1) AND METHODS OF USE.
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
WO2025010229A3 (en) T-cell receptors targeting foxm1 and methods of use thereof
WO2024220520A3 (en) T-cell receptors targeting her2 and methods of use thereof
WO2024163607A3 (en) T-cell receptors targeting egfr and methods of use thereof
WO2006044410A3 (en) A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
WO2023129870A3 (en) ANTIBODIES SPECIFICALLY RECOGNIZING C5aR1 AND USES THEREOF
WO2024026468A3 (en) Methods and compositions regarding cyclic peptides for use with antibodies and antibody fragments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24836515

Country of ref document: EP

Kind code of ref document: A2